Inogen to launch new POC this year
By HME News Staff
Updated 12:08 PM CST, Tue January 10, 2023
GOLETA, Calif. – Inogen has received 510(k) clearance from the U.S. Food and Drug Administration for its latest portable oxygen concentrator, the Rove 4. The company has already launched the Rove 6, a new and improved six-setting device, in European countries, where reimbursement is grandfathered, and it plans to launch the Rove 4, a four-setting device, in the U.S. by the back half of 2023. Inogen has also received European Medical Device Regulation certification to sell and commercialize its Inogen One G4 and the updated version of its Inogen One G5 POCs in the E.U. “We are pleased to announce the receipt of both the EU MDR certification and US FDA clearance,” said Nabil Shabshab, President and Chief Executive Officer. “This is an important next step in Inogen cementing its commitment to continue leading POC innovations to serve patients in need of oxygen therapy around the world. The Rove series will serve as our next generation POC platform with product launches being planned for 2023. We are excited about these new products and the progress in the overall innovation roadmap towards next generation offerings to serve COPD patients and beyond.”
Comments